BANB stock is Bachem Holding AG, the Swiss peptide maker on the SIX exchange. See what drives the shares and how US investors can buy them in practice.
BANB stock is the ticker for Bachem Holding AG, a Swiss peptide manufacturer listed on the SIX Swiss Exchange. The company produces research peptides for laboratories and commercial-scale peptide active ingredients for pharmaceutical partners. Because Bachem has no mainstream US listing, American investors usually need a broker that offers access to Swiss markets.
What Bachem Holding AG Actually Does
Bachem was founded in 1971 and is headquartered in Bubendorf, Switzerland. It builds peptides — short chains of amino acids — at scales ranging from milligrams for laboratory use to large commercial batches for approved drugs.
The business breaks into two broad revenue streams:
- Commercial peptide APIs: Peptide drug substances manufactured for pharma and biotech customers under long-term supply agreements.
- Research and specialty peptides: Catalog and custom peptides, reagents, and related products sold to labs, diagnostics companies, and academic groups.
The commercial side is what moves the share price. Peptide drugs, including GLP-1 therapies, require manufacturing capacity that very few companies can build and validate.
If you are new to the sector, it helps to start with a plain-language answer to what is peptide before judging any manufacturer's pipeline. Peptides are amino acid chains, and making them at commercial scale is a chemistry, purification, and regulatory problem rather than a simple volume problem.
Why BANB Stock Moves
Bachem's valuation is tied to expectations about peptide demand and the company's ability to convert that demand into revenue.
- GLP-1 news: Semaglutide and tirzepatide are peptides, so headlines about obesity and diabetes drug demand feed directly into sentiment on peptide manufacturers.
- Capacity milestones: New plants, expanded manufacturing suites, and site approvals are concrete catalysts.
- Guidance and order intake: Bachem reports on a semi-annual cadence, so updates are less frequent and each one lands harder.
- Customer concentration: A small number of large pharmaceutical customers account for a meaningful share of commercial revenue.
- Currency: Revenue arrives in several currencies while costs are largely Swiss franc based, so a strong franc can pressure reported results.
How US Investors Buy BANB Stock
BANB trades on the SIX Swiss Exchange in Swiss francs. It is not a US-listed security, and there is no widely traded American Depositary Receipt for the stock.
- You generally need an international brokerage account or a platform with Swiss exchange access.
- Your total return includes movement between the US dollar and the Swiss franc.
- Switzerland applies a 35% withholding tax to dividends paid to foreign investors; US residents can often reduce that to a 15% treaty rate with the correct paperwork.
- Liquidity is thinner than for a large US stock, so limit orders are sensible.
- Do not confuse ticker BANB with similarly named US tickers such as BANC or BANR.
Bachem Compared With Other Peptide Manufacturers
Bachem competes with a small group of listed manufacturers and a larger group of privately held specialists. The table below shows roughly where each one sits.
| Company | Primary listing | Role in the peptide chain | Access for US investors |
|---|---|---|---|
| Bachem Holding AG | SIX Swiss Exchange (BANB) | Commercial peptide APIs and research peptides | International broker required; CHF exposure |
| GenScript Biotech | Hong Kong (1548) | Peptide synthesis and life-science services | Hong Kong listing via global brokers |
| Asymchem | Shenzhen and Hong Kong | Small-molecule and peptide CDMO work | China A-shares or H-shares |
| Pharmaron | Shenzhen and Hong Kong | Integrated CRO and CDMO services | China A-shares or H-shares |
| Biosynth | Privately held | Reagents and custom synthesis | Not directly investable |
| AmbioPharm | Privately held (US) | Peptide CDMO manufacturing | Not directly investable |
Investors who want a wider industry comparison often start with genscript stock, which covers peptide synthesis alongside broader life-science tools and biologics services. Asymchem stock and pharmaron stock trade in Shenzhen and Hong Kong and offer a different mix of contract development and manufacturing exposure.
Some investors cross-check the best chinese peptide company candidates to gauge how much capacity is being added in China. Chinese suppliers compete aggressively on price, while Bachem positions itself around regulated, large-scale commercial manufacturing.
Risks Worth Understanding
- Capital intensity: Peptide plants are expensive and take years to fill, so returns lag spending.
- In-house competition: Large drugmakers are building their own peptide capacity, which could reduce outsourced volumes over time.
- Valuation: Enthusiasm for peptide exposure has pushed the multiple up, so growth has to show up in reported numbers.
- Regulatory and quality risk: A failed inspection or batch issue at a manufacturing site can disrupt shipments.
- Concentration and currency: A handful of large customers and a strong Swiss franc both cut against results.
Nothing in this article is investment advice. Speak with a licensed financial professional and a tax advisor before buying foreign-listed shares.
How to Track BANB Stock
- Read Bachem's semi-annual and annual reports for revenue by segment, order intake, and capital spending guidance.
- Follow capacity news, including plant construction and site approvals.
- Watch GLP-1 prescribing trends and manufacturing investments by the major obesity drugmakers.
- Compare gross margin trends across several years instead of a single period.
- Check Swiss analyst coverage and CHF exchange-rate trends.
Bachem is a manufacturing story with long lead times, which means the stock often moves on expectations before the revenue appears in the accounts.
Frequently Asked Questions
What is BANB stock?
BANB is the ticker for Bachem Holding AG, a Swiss peptide manufacturer listed on the SIX Swiss Exchange. The company makes commercial peptide active ingredients for pharmaceutical customers and research peptides for laboratories. It is not listed on a major US exchange.
Can US investors buy BANB stock?
Yes, but usually through an international brokerage account with access to Swiss markets, because there is no widely traded US ADR. Trades settle in Swiss francs, so returns include currency movement. Switzerland also withholds 35% tax on dividends, which US residents can often reduce to 15% under the US-Switzerland treaty.
Why does BANB stock react to GLP-1 news?
GLP-1 drugs such as semaglutide and tirzepatide are peptides, and producing them at commercial scale requires specialized manufacturing capacity. Bachem is one of the larger independent peptide manufacturers, so headlines about obesity drug demand, capacity expansions, and drugmaker supply plans affect how investors value the shares.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.